Biomarkers Of Lung InVolvement In ASMD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

68 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-12-05

Study Completion Date

2024-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to characterize ASMD patients' breath profile, exhaled breath and condensate as compared to healthy controls to identify specific volatile and non-volatile compounds that reflect inflammatory processes, fibrotic processes or sphingolipid accumulation in the lungs.

Participants will be provided exhaled breath samples in three ways (breath profile, volatile compounds and condensate). ASMD patients will be compared to age- and sex-matched healthy controls.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath

NCT06528418

Lung Cancer Lung Infection COPD +13 more

RECRUITING

Identification of Volatile Organic Compounds in Exhaled Air During Exacerbation of Chronic Obstructive Pulmonary Disease

NCT02529891

Chronic Obstructive Pulmonary Disease

TERMINATED

Inhalation Profiling of Idiopathic Pulmonary Fibrosis (IPF) Patients

NCT02058602

Idiopathic Pulmonary Fibrosis

COMPLETED PHASE1

Evaluation of Novel Lung Function Parameters in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT02827721

COPD Obstructive Ventilation Disorder Pulmonary Emphysema

UNKNOWN

Non-invasive Prognostication of COVID-19 Patients by Use of Biomarkers in Exhaled Breath Condensate

NCT04598620

Covid19 Corona Virus Infection

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Rationale: Acid sphingomyelinase deficiency (ASMD) is a lysosomal storage disease in which sphingomyelin accumulates due to a deficiency of the enzyme acid sphingomyelinase. The most common manifestations of the chronic visceral subtype of this disease are hepatosplenomegaly and interstitial lung disease (ILD). Currently, enzyme replacement therapy is under investigation and will likely become available in the near future. The first results indicate that pulmonary involvement may be responsive to treatment. In order to identify those patients that will potentially benefit from therapy, biomarkers for lung injury can be helpful. Compounds measured in exhaled breath and exhaled breath condensate are extensively studied in common lung diseases and increasingly in ILD. These compounds are of interest since they provide information directly form the lung compartment and are collected non-invasively.

Objective: Our aim is to characterize ASMD patients' breath profile, exhaled breath and condensate as compared to healthy controls to identify specific volatile and non-volatile compounds that reflect inflammatory processes, fibrotic processes or sphingolipid accumulation in the lungs.

Study design: This study comprises a cross-sectional case-control part and a prospective cohort part. In the cross-sectional part, exhaled breath samples with volatile and non-volatile compounds of ASMD patients and healthy controls will be collected. After potential biomarkers are identified in the cross-sectional part, patients will enter the longitudinal part in which the prognostic and monitoring value of these markers will be evaluated using clinical parameters.

Study population: ASMD patients ≥ 12 years of age with a confirmed diagnosis of the chronic visceral type will be included as well as age-, sex- and smoking status-matched healthy controls with a ratio of 1:3.

Main study parameters/endpoints: Inflammatory markers, fibrotic markers and markers of sphingolipid accumulation will be measured in exhaled breath. Breath profiles will be measured with eNose, volatile compounds will be measured with GC-MS and non-volatile compounds will be measured in exhaled breath condensates using UPLC-MS/MS.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Sampling of exhaled breath yields no risk: at most, patients might suffer from dizziness or mild dyspnea. Patients will not directly benefit from participation in the study. We aim to identify biomarkers reflecting lung involvement of ASMD and in that respect the results of the study may improve clinical care in the future for the patients participating in the study or any ASMD patient with similar characteristics.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asmd, Visceral Type

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

This study comprises a cross-sectional case-control part and a prospective cohort part. In the cross-sectional part, exhaled breath samples with volatile and non-volatile compounds of ASMD patients and healthy controls will be collected. After potential biomarkers are identified in the cross-sectional part, patients will enter the longitudinal part in which the prognostic and monitoring value of these markers will be evaluated using clinical parameters.

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.